Citations

Bacterial Toxin Research Citations

We’ve gathered published citations for the past many years so that researchers can easily review at their convenience from among the thousands of published articles, how they might use our products in detail or apply these ideas to their own novel thinking for new research.

Search through, read and share our information rich citations below!

Contact us with any questions.

4918 total record number 290 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by the cell/animal/assay/protein/research or publication
Page 11 out of 492
4918 citations found

Myelin-reactive B cells exacerbate CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner

Fazazi, MR;Doss, PMIA;Pereira, R;Fudge, N;Regmi, A;Joly-Beauparlant, C;Akbar, I;Yeola, AP;Mailhot, B;Baillargeon, J;Grenier, P;Bertrand, N;Lacroix, S;Droit, A;Moore, CS;Rojas, OL;Rangachari, M;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • is extract (BD Difco). On day 0 and day 2 post-immunization, mice received 200?ng pertussis toxin (List Biological Laboratories) intraperitoneally. For p19 blockade, mice were administered anti-p19 (clone G23-8) or isotype (rIgG1, clone HRPM; both BioXcell), 1?mg, on d-1 and d+6 post-immunization56. For the comparison of Th17 cell pathogenicity in the presence of WT or IgH[MOG] B cells (Fig. 3d), 10-week-old NOD.Scid mice were first passively infused i.v. with 2?×?106 CD19+ WT or IgH[MOG] B cells from unimmunized donors. Fourteen days post-infusion, 2?

Human NMO-IgG Induced Different Pathological and Immunological Changes in the CNS and Peripheral Tissues of Mice

Xiang, W;Bai, S;Wang, K;Peng, J;Wang, Z;Han, L;Xie, C;Guan, Y;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • lete Freund’s adjuvant (BD Difco, Franklin Lakes, NJ, USA) at 4 sites. Then, they were injected (i.p.) with 200 ng pertussis toxin (List Biological Laboratories, Campbell, CA, USA) on days 4 and 7 after immunization. Mice started to receive injections (i.p.) of NMO-IgG on day 0 for 8 consecutive days (5 mg NMO-IgG/day). The control group received injections of adjuvant, pertussis toxin, and the same amount of control-IgG. 2.3 Detection of Motor Impairments

Retrograde adenosine/A2A receptor signaling facilitates excitatory synaptic transmission and seizures

Nasrallah, K;Berthoux, C;Hashimotodani, Y;Chávez, AE;Gulfo, MC;Luján, R;Castillo, PE;

Product: Botulinum Neurotoxin Type B Light Chain, Recombinant

  • ANA-12 Tocris Bioscience Cat#4781 Botulinum toxin-B List biological Cat# 620A H89 dihydrochloride Tocris Bioscience Cat#2910

The Cystic Fibrosis Transmembrane Regulator Controls Tolerogenic Responses to Food Allergens in Mice and Humans

Emmenegger, M;Zografou, C;Dai, Y;Hoyt, L;Gudneppanavar, R;Chincisan, A;Rehrauer, H;Noé, F;Zajac, N;Meisl, G;Schneider, M;Nguyen, H;Höpker, K;Knowles, T;Sospedra, M;Martin, R;Ring, A;Leeds, S;Eisenbarth, S;Egan, M;Bruscia, E;Aguzzi, A;

Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae

  • was dissolved in 200 µl of 0.2 mol sodium bicarbonate buffer with or without 10 µg of cholera toxin (List Biologicals, Campbell, Calif) as an adjuvant and delivered by oral gavage. Blood was collected from the retro-orb

Merkel Cell Polyomavirus targets SET/PP2A complex to promote cellular proliferation and migration

Gupta, P;Venuti, A;Savoldy, M;Harold, A;Zito, FA;Taverniti, V;Romero-Medina, MC;Galati, L;Sirand, C;Shahzad, N;Shuda, M;Gheit, T;Accardi, R;Tommasino, M;

Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae

  • ), 5 mg/ml insulin (Sigma-Aldrich), 400 ?g/ml hydrocortisone (SIGMA), 10 mg/ml ciprofloxacin hydrochloride (EUROMEDEX) and 20 mg of cholera toxin (List Biological

Oral vancomycin treatment alters serum levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAE

Bianchimano, P;Leone, P;Smith, E;Gutierrez-Vazquez, C;Wind-andersen, E;Bongers, G;Cristancho, S;Weiner, H;Clemente, J;Tankou, S;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • 's adjuvant (CFA) (BD Difco) per mouse, injected subcutaneously into each flank, followed by intraperitoneal administration of 150 ng of pertussis toxin (List Biological

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • inal subcutaneous injection. They were also intraperitoneally injected with 500 ng pertussis toxin (List Biological) at the time of immunization and again after 48 h. Thus, an EAE model was established. Mouse body weights were recorded daily post-immunization (PI). Researchers were blinded to experimental conditions and evaluated the EAE severity using an international five-poin

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • ubcutaneously injected with 200 ?g MOG35-55 in complete Freund's adjuvant (5 mg/ml, Sigma-Aldrich). Pertussis Toxin (200 ng, List Biological Laboratories) was injected intravenously twice on 0 and 2 days postimmunization (dpi.). The immunized mice were monitored daily with body weight measurement and clinical scores evaluation. EAE symptoms were scored daily as follows: 0, no clinical signs; 0.5, partially limp tail; 1, paralyzed tail; 1.5, hindlimb pare

Effects of melatonin on the management of multiple sclerosis: A scoping review on animal studies

Bandehagh, H;Gozalpour, F;Mousavi, A;Ghavshough, M;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • Injection of MOG35-55, 300 ng of pertussis toxin (List Biological Labs, Campbell, CA, USA) intraperitoneally, into all animals, on days 0 and 2

Transcriptional network analysis of peripheral blood leukocyte subsets in multiple sclerosis identifies a pathogenic role for a cytotoxicity-associated gene network in myeloid cells

Jordan, MA;Gresle, MM;Gemiarto, AT;Stanley, D;Smith, LD;Laverick, L;Spelman, T;Stankovich, J;Willson, AM;Dinh, XT;Johnson, L;Robertson, K;Reid, CA;Field, J;Butzkueven, H;Baxter, AG;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • tems, Sparks, MD) at day0 between the shoulder blades. The mice also receivedintraperitoneal injection of 250 ng PTX (List BiologicalLaboratories, Campbell, CA) at the day of immunization and2 days later. Disease progression was scored daily from day 8after initial injection, for 30 days. 42 Clinical symptoms of EAEwere scored as follows: 0, no symptoms; 0.5, ta